Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine.
about
Pneumococcal vaccination during pregnancy for preventing infant infectionPneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of agePneumococcal vaccination during pregnancy for preventing infant infectionDevelopment of a model of focal pneumococcal pneumonia in young ratsSafety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infantsA current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: Considerations for the routinely-recommended, pediatric PCV dosing schedule in the United StaDiscovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodiesPriming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.Clonal association between Streptococcus pneumoniae serotype 23A, circulating within the United States, and an internationally dispersed clone of serotype 23F.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Distribution of Streptococcus pneumoniae serotypes responsible for penicillin resistance and the potential role of new conjugate vaccines in New Caledonia.Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in ScotlandComparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.Conjugated heptavalent pneumococcal vaccine.Expression of the type 1 pneumococcal pilus is bistable and negatively regulated by the structural component RrgAUnexplained fever in young children: how to manage severe bacterial infectionPractice guidelines for the management of febrile infants less than 90 days of age at the ambulatory network of a large pediatric health care system in the United States: summary of new evidence.Vaccination considerations in the asplenic patient.Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway.Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention.Treatment and prevention strategies to combat pediatric pneumococcal meningitis.How useful is C-reactive protein in detecting occult bacterial infection in young children with fever without apparent focus?Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin.Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein.Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.Streptococcus pneumoniae serotype 19A meningitis in well-vaccinated immunocompetent 13-month-old child: a case of PCV13 failure.Immunoblot method to detect Streptococcus pneumoniae and identify multiple serotypes from nasopharyngeal secretions.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.Invasive pneumococcal disease in infants younger than 60 days.Bacteremia in Early Infancy: Etiology and Management.Invasive pneumococcal infection despite 7-valent conjugated vaccine.Stability of serotypes during nasopharyngeal carriage of Streptococcus pneumoniaeEffectiveness and cost-effectiveness of general immunisation of infants and young children with the heptavalent conjugated pneumococcal vaccine.Management of febrile children in the conjugate pneumococcal vaccine era.Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.Engineered PRINT(®) nanoparticles for controlled delivery of antigens and immunostimulants.Antimicrobial susceptibility of invasive and lower respiratory tract isolates of Streptococcus pneumoniae, 1998 to 2007.
P2860
Q24244583-9581D5B5-9ECD-4AD7-94CC-97E7E2A42A05Q24245934-B80C57CB-98D7-4D88-879A-B388A4D88D08Q24246895-71748A39-70BA-4F22-8E61-A0F0C8887CB8Q24795480-3DF59B64-B25E-4752-819F-D307C9B8F0CDQ24795590-71913098-EC06-4C8B-836F-2C0D113F6DE6Q28085452-F570E3BB-A156-4AD9-9394-E0888C66A297Q33312893-C05AEDA5-90A1-46F3-90DA-6370CC9314C4Q34072420-520AD1D2-6E45-40E6-8F6D-A3BEF85C76FCQ34143742-50341A3E-3837-4DE7-BB1E-DB2E6B27DB80Q34170021-48FB401D-E91D-4B09-967B-BFE1D65A8ED0Q34231573-072D0FBA-7AE0-42D6-BCD4-085CD897820CQ34569142-097E138E-B576-446F-9938-A08B59E507FDQ34774773-84FE3BAC-8A6D-45A4-A05F-A9BC9A7AF4C1Q34796973-A5157C58-DEDD-4AC0-AD03-12157CF03134Q35139321-CE798B0D-954A-41B7-A8EE-310DB03A0B56Q35578731-9265FA81-EBA0-48F4-B734-9A8515A0DDF6Q35669488-FDA8298A-07A4-4208-9A0C-8AA52ADE10CCQ36066242-5D94C46A-9C4C-46CF-A026-6F50CCF5A5BAQ36080545-693CF308-8850-4A4F-B8EF-D4225E9D7159Q36128243-4621C355-14DD-4419-AC6B-3C6C28AAFB01Q36227569-61E447F0-5871-41F3-8592-A7820FC574A1Q36257961-522170DE-FA97-45C5-9CB0-4ABE56887C23Q36278050-7193725F-6EC7-4D54-B526-9D5C60002252Q36484408-48CA5328-9B74-4DEF-981F-BE2CFB07F217Q36505493-11BEE9DC-7B1C-4CD4-AB0E-8C15FF729A57Q36562085-340AB702-DAA5-482D-BEB7-650EE2AF66FEQ36670897-CEA9925B-8DCA-4298-A3C2-65428FCA53D8Q36871048-5FE3671A-1FEB-4A0D-A7C2-78D1D68A9376Q37389566-5BE52470-B4FF-429A-AE99-EC7ADEDA6E9FQ37419564-ABBC2690-C113-4E7D-95BB-A3D47F9758DAQ37621064-080B4914-948C-4A17-954D-C5DA5832D5E9Q37982359-538B5E27-C4AB-4B0A-8536-7EBCF6B89309Q38678086-534AA195-E765-474C-981C-4E686150866AQ38678793-5D198ADF-0096-4226-8FA0-E4F37E75AC37Q39732954-70AB8167-0694-4609-BECE-AA7D2F337C5EQ40457806-127A1B81-943D-43E3-8D52-D7EE1B984741Q40540155-8A0F6477-07BC-4EE5-9EDC-C6F119D1E380Q41095079-300F6182-5D0E-415A-B474-2213C55E8642Q42206456-7F350D7C-FD00-40C1-8FD5-87D98DF5847EQ42789542-4258C446-689E-4C40-A1CC-07DBFFCDB47E
P2860
Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@ast
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@en
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@nl
type
label
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@ast
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@en
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@nl
prefLabel
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@ast
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@en
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@nl
P2093
P1476
Postlicensure evaluation of th ...... neumococcal conjugate vaccine.
@en
P2093
P304
P356
10.1097/00006454-200112000-00002
P577
2001-12-01T00:00:00Z